Antivirals Against the Chikungunya Virus
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Chikungunya Fever: Epidemiology, Clinical Syndrome, Pathogenesis
Antiviral Research 99 (2013) 345–370 Contents lists available at SciVerse ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy ⇑ Simon-Djamel Thiberville a,b, , Nanikaly Moyen a,b, Laurence Dupuis-Maguiraga c,d, Antoine Nougairede a,b, Ernest A. Gould a,b, Pierre Roques c,d, Xavier de Lamballerie a,b a UMR_D 190 ‘‘Emergence des Pathologies Virales’’ (Aix-Marseille Univ. IRD French Institute of Research for Development EHESP French School of Public Health), Marseille, France b University Hospital Institute for Infectious Disease and Tropical Medicine, Marseille, France c CEA, Division of Immuno-Virologie, Institute of Emerging Diseases and Innovative Therapies, Fontenay-aux-Roses, France d UMR E1, University Paris Sud 11, Orsay, France article info abstract Article history: Chikungunya virus (CHIKV) is the aetiological agent of the mosquito-borne disease chikungunya fever, a Received 7 April 2013 debilitating arthritic disease that, during the past 7 years, has caused immeasurable morbidity and some Revised 21 May 2013 mortality in humans, including newborn babies, following its emergence and dispersal out of Africa to the Accepted 18 June 2013 Indian Ocean islands and Asia. Since the first reports of its existence in Africa in the 1950s, more than Available online 28 June 2013 1500 scientific publications on the different aspects of the disease and its causative agent have been pro- duced. Analysis of these publications shows that, following a number of studies in the 1960s and 1970s, Keywords: and in the absence of autochthonous cases in developed countries, the interest of the scientific commu- Chikungunya virus nity remained low. -
Antibody-Mediated Enhancement Aggravates Chikungunya Virus
www.nature.com/scientificreports OPEN Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity Received: 14 July 2017 Fok-Moon Lum 1,2, Thérèse Couderc3,4, Bing-Shao Chia1,8, Ruo-Yan Ong1,9, Zhisheng Her1,10, Accepted: 17 January 2018 Angela Chow5, Yee-Sin Leo5, Yiu-Wing Kam1, Laurent Rénia1, Marc Lecuit 3,4,6 & Published: xx xx xxxx Lisa F. P. Ng1,2,7 The arthropod-transmitted chikungunya virus (CHIKV) causes a fu-like disease that is characterized by incapacitating arthralgia. The re-emergence of CHIKV and the continual risk of new epidemics have reignited research in CHIKV pathogenesis. Virus-specifc antibodies have been shown to control virus clearance, but antibodies present at sub-neutralizing concentrations can also augment virus infection that exacerbates disease severity. To explore this occurrence, CHIKV infection was investigated in the presence of CHIKV-specifc antibodies in both primary human cells and a murine macrophage cell line, RAW264.7. Enhanced attachment of CHIKV to the primary human monocytes and B cells was observed while increased viral replication was detected in RAW264.7 cells. Blocking of specifc Fc receptors (FcγRs) led to the abrogation of these observations. Furthermore, experimental infection in adult mice showed that animals had higher viral RNA loads and endured more severe joint infammation in the presence of sub-neutralizing concentrations of CHIKV-specifc antibodies. In addition, CHIKV infection in 11 days old mice under enhancing condition resulted in higher muscles viral RNA load detected and death. These observations provide the frst evidence of antibody-mediated enhancement in CHIKV infection and pathogenesis and could also be relevant for other important arboviruses such as Zika virus. -
COVID-19 Drugs: Are There Any That Work? 24 August 2020, by from Mayo Clinic News Network, Mayo Clinic News Network
COVID-19 drugs: Are there any that work? 24 August 2020, by From Mayo Clinic News Network, Mayo Clinic News Network dysfunction and lung injury from inflammation. A recent study found it reduced deaths by about 30% for people on ventilators and by about 20% for people who needed supplemental oxygen. The U.S. National Institutes of Health has recommended this drug for people hospitalized with COVID-19 who are on mechanical ventilators or need supplemental oxygen. Other corticosteroids, such as prednisone, methylprednisolone or hydrocortisone, may be used if dexamethasone isn't available. However, their effectiveness isn't yet known. Dexamethasone and other corticosteroids may be harmful if given for less severe COVID-19 infection. Credit: Unsplash/CC0 Public Domain Anti-inflammatory therapy. Researchers study many anti-inflammatory drugs to treat or prevent dysfunction of several organs and lung injury from infection-associated inflammation. Question: I've heard several drugs mentioned as possible treatments for COVID-19. What are they Immune-based therapy. Researchers are studying and how do they work? the use of a type of immune-based therapy called convalescent plasma. Convalescent plasma is Answer: Although there is no product approved by blood donated by people who've recovered from the Food and Drug Administration to treat COVID-19. It is used to treat people who are coronavirus disease 2019 (COVID-19), many seriously ill with the disease. medications are being tested. Drugs being studied that have uncertain One investigational drug called remdesivir has effectiveness. Researchers are studying been authorized by the FDA for emergency use amlodipine, ivermectin, losartan and famotidine. -
NSP4)-Induced Intrinsic Apoptosis
viruses Article Viperin, an IFN-Stimulated Protein, Delays Rotavirus Release by Inhibiting Non-Structural Protein 4 (NSP4)-Induced Intrinsic Apoptosis Rakesh Sarkar †, Satabdi Nandi †, Mahadeb Lo, Animesh Gope and Mamta Chawla-Sarkar * Division of Virology, National Institute of Cholera and Enteric Diseases, P-33, C.I.T. Road Scheme-XM, Beliaghata, Kolkata 700010, India; [email protected] (R.S.); [email protected] (S.N.); [email protected] (M.L.); [email protected] (A.G.) * Correspondence: [email protected]; Tel.: +91-33-2353-7470; Fax: +91-33-2370-5066 † These authors contributed equally to this work. Abstract: Viral infections lead to expeditious activation of the host’s innate immune responses, most importantly the interferon (IFN) response, which manifests a network of interferon-stimulated genes (ISGs) that constrain escalating virus replication by fashioning an ill-disposed environment. Interestingly, most viruses, including rotavirus, have evolved numerous strategies to evade or subvert host immune responses to establish successful infection. Several studies have documented the induction of ISGs during rotavirus infection. In this study, we evaluated the induction and antiviral potential of viperin, an ISG, during rotavirus infection. We observed that rotavirus infection, in a stain independent manner, resulted in progressive upregulation of viperin at increasing time points post-infection. Knockdown of viperin had no significant consequence on the production of total Citation: Sarkar, R.; Nandi, S.; Lo, infectious virus particles. Interestingly, substantial escalation in progeny virus release was observed M.; Gope, A.; Chawla-Sarkar, M. upon viperin knockdown, suggesting the antagonistic role of viperin in rotavirus release. Subsequent Viperin, an IFN-Stimulated Protein, studies unveiled that RV-NSP4 triggered relocalization of viperin from the ER, the normal residence Delays Rotavirus Release by Inhibiting of viperin, to mitochondria during infection. -
COVID-19: Predicting Inhibition of the Main Protease and Therapeutic Intracellular Accumulation and Plasma and Lung Concentratio
COVID-19: predicting inhibition of the main protease and therapeutic intracellular accumulation and plasma and lung concentrations of repurposed inhibitors Clifford Fong To cite this version: Clifford Fong. COVID-19: predicting inhibition of the main protease and therapeutic intracellu- lar accumulation and plasma and lung concentrations of repurposed inhibitors. [Research Report] Eigenenergy. 2020. hal-02917312 HAL Id: hal-02917312 https://hal.archives-ouvertes.fr/hal-02917312 Submitted on 20 Aug 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. COVID-19: predicting inhibition of the main protease and therapeutic intracellular accumulation and plasma and lung concentrations of repurposed inhibitors Clifford W. Fong Eigenenergy, Adelaide, South Australia, Australia. Email: [email protected] Keywords: COVID-2019 or SARS-CoV-2; SARS-CoV; MERS; 3C-like protease, or 3CLpro, pro or M ; inhibition; IC50, EC50, EC90, host cell membrane transport, AUC, Cmax, linear free energy relationships, HOMO-LUMO; quantum mechanics; Abbreviations: Structure -
Identification and Characterisation of Human Cytomegalovirus-Mediated Degradation of Helicase-Like Transcription Factor
Identification and Characterisation of Human Cytomegalovirus-Mediated Degradation of Helicase-Like Transcription Factor Kai-Min Lin Department of Medicine Cambridge Institute for Medical Research University of Cambridge This dissertation is submitted for the degree of Doctor of Philosophy Fitzwilliam College September 2020 Declaration I hereby declare, that except where specific reference is made to the work of others, the contents of this dissertation are original and have not been submitted in whole or in part for consideration for any other degree of qualification in this, or any other university. This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except as where specified in the text and acknowledgments. This dissertation does not exceed the specified word limit of 60,000 words as defined by the Degree Committee, excluding figures, photographs, tables, appendices and bibliography. Kai-Min Lin September, 2020 I Summary Identification and characterisation of human cytomegalovirus-mediated degradation of helicase-like transcription factor Kai-Min Lin Viruses are known to degrade host factors that are important in innate antiviral immunity in order to infect successfully. To systematically identify host proteins targeted for early degradation by human cytomegalovirus (HCMV), the lab developed orthogonal screens using high resolution multiplexed mass spectrometry. Taking advantage of broad and selective proteasome and lysosome inhibitors, proteasomal degradation was found to be heavily exploited by HCMV. Several known antiviral restriction factors, including components of cellular promyelocytic leukemia (PML) were enriched in a shortlist of proteasomally degraded proteins during infection. A particularly robust novel ‘hit’ was helicase-like transcription factor (HLTF), a DNA repair protein that participates in error-free repair of stalled replication forks. -
Lora Grainger Dissertation 6 23 10
Characterization of the Transcripts that Encode pUL138, a Latency Determinant, During Human Cytomegalovirus Infection Item Type text; Electronic Dissertation Authors Grainger, Lora Ann Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 24/09/2021 15:04:11 Link to Item http://hdl.handle.net/10150/195915 1 CHARACTERIZATION OF THE TRANSCRIPTS THAT ENCODE PUL138, A LATENCY DETERMINANT, DURING HUMAN CYTOMEGALOVIRUS INFECTION by Lora A. Grainger Copyright © Lora A. Grainger 2010 A Dissertation Submitted to the Faculty of the DEPARTMENT OF IMMUNOBIOLOGY In Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 2010 2 THE UNIVERSITY OF ARIZONA GRADUATE COLLEGE As members of the Dissertation Committee, we certify that we have read the dissertation prepared by Lora A. Grainger entitled: Characterization of the Transcripts that Encode pUL138, a Latency Determinant, During Human Cytomegalovirus Infection. We recommend that it be accepted as fulfilling the dissertation requirement for the Degree of Doctor of Philosophy. _____________________________________________________Date: 6/15/10 Dr. Nafees Ahmad _____________________________________________________ Date: 6/15/10 Dr. Lonnie Lybarger _____________________________________________________ Date: 6/15/10 Dr. Carol Dieckmann Final approval and acceptance of this dissertation is contingent upon the candidate’s submission of the final copies of the dissertation to the Graduate College. I hereby certify that I have read this dissertation prepared under my direction and recommend that it be accepted as fulfilling the dissertation requirement _____________________________________________________Date: 6/15/10 Dissertation Director: Dr. -
Holmes Washington 0250E 22
©Copyright 2020 Daniel Holmes Identification of Targetable Vulnerabilities During Latent KSHV Infection Daniel Holmes A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2020 Reading Committee: Michael Lagunoff, Chair Adam Philip Geballe Jason G Smith Program Authorized to Offer Degree: Department of Microbiology University of Washington Abstract Identification of Targetable Vulnerabilities During Latent KSHV Infection Daniel Holmes Chair of the Supervisory Committee: Professor Michael Lagunoff Department of Microbiology Viruses are defined as obligate intracellular parasites that require host processes to repli- cate. Latent virus life cycles are no exception to this definition, as viruses are still reliant on host machinery for continued proliferation and maintenance of viral genomes, even in the absence of lytic replication. In this thesis, I used essentiality screening to identify host factors on which Kaposi's Sarcoma Associated Herpesvirus (KSHV) relies for the proliferation and survival of latently infected cells. KSHV is the etiological agent of Kaposi's Sarcoma (KS), an endothelial cell-based tumor where more than 90% of the endothelial cells in the tumor are latently infected with KSHV. While traditional therapies for herpesviruses target lytic replication, the prevalence of latency in KS necessitates exploration of options for intervening in this stage of the viral life cycle. I performed CRISPR/Cas9 screening using lentiviral vec- tors encoding a library of single guide RNAs (sgRNAs) targeting every protein coding gene in the human genome. I compared mock infected and KSHV infected endothelial cells eight days post infection to identify genes essential to latent KSHV infection. -
For Viperin/Cig5 Response in Human Fetal Astrocytes
TLR3 Ligation Activates an Antiviral Response in Human Fetal Astrocytes: A Role for Viperin/cig5 This information is current as Mark A. Rivieccio, Hyeon-Sook Suh, Yongmei Zhao, of October 1, 2021. Meng-Liang Zhao, Keh Chuang Chin, Sunhee C. Lee and Celia F. Brosnan J Immunol 2006; 177:4735-4741; ; doi: 10.4049/jimmunol.177.7.4735 http://www.jimmunol.org/content/177/7/4735 Downloaded from References This article cites 40 articles, 16 of which you can access for free at: http://www.jimmunol.org/content/177/7/4735.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 1, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology TLR3 Ligation Activates an Antiviral Response in Human Fetal Astrocytes: A Role for Viperin/cig51 Mark A. Rivieccio,2,3* Hyeon-Sook Suh,2* Yongmei Zhao,* Meng-Liang Zhao,* Keh Chuang Chin,‡ Sunhee C. -
What's in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV And
What’s in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV and TB Treatments in Clinical Trials by Rob Camp, Richard Jefferys, Tracy Swan & Javid Syed edited by Mark Harrington & Bob Huff Treatment Action Group New York, NY, USA July 2005 e thymidine • BI-201 • Racivir (PSI 5004) • TMC-278 • Diarylpyrimidine (DAPY) • 640385 • Reverset (D-D4FC) • JTK-303 • UK-427 (maraviroc) • Amdoxovir • AMD-070 • Vicriviroc LIPO-5 • GTU-Multi-HIV • pHIS-HIV-B • rFPV-HIV-B • ADMVA • GSK Protein HIV Vaccine TBC-M335 (MVA) • TBC-F357 (FPV) • TBC-F349 (FPV) • LIPO-4T (LPHIV-1) • LFn-p24 • H G • Oligomeric gp140/MF59 • VRC-HIVDNA-009-00-VP • PolyEnv1 • ISS P-001 • EP HIV- • BufferGel • Lactin-V • Protected Lactobacilli in combination with BZK • Tenofovir/PMPA G ulose acetate/CAP) • Lime Juice • TMC120 • UC-781 • VivaGel (SPL7013 gel) • ALVAC Ad5 • Autologous dendritic cells pulsed w/ALVAC • Autologous dendritic cell HIV vaccination x • Tat vaccine • GTU-nef DNA vaccine • Interleukin-2 (IL-2) • HE2000 • Pegasys (peginter L-4/IL-13 trap • Serostim • Tucaresol • MDX-010 anti-CTLA4 antibody • Cyclosporine A • 496 • HGTV43 • M87o • Vertex • VX-950 • Idenix • Valopicitabine (NM283) • JTK-003 mplant • Albuferon • Celgosivir (MBI-3253) • IC41 • INN0101 • Tarvicin • ANA971 (oral) floxacin, Tequin • J, TMC207 (ex R207910) • LL-3858 • M, moxifloxacin, Avelox • PA-824 Acknowledgements. Thanks to our intrepid editors, Bob Huff, copy-editor Andrea Dailey, and proof-reader Jen Curry, to awesome layout expert Lei Chou, to webmaster Joel Beard, to Joe McConnell for handling administrative matters related to the report, and most of all to the board and supporters of TAG for making our work possible. -
Differences in Clinical Outcomes Among Hepatitis C Genotype 1
Clinical and Experimental Gastroenterology Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis Eric Druyts1 Background: With the development of new direct acting antiviral (DAA) therapy for hepatitis Edward J Mills1,2 C, the backbone peginterferon alpha used may be of importance in maximizing treatment Jean Nachega3 outcomes. To this end, the rates of sustained virologic response (SVR), relapse, and treatment Christopher O’Regan4 discontinuation among hepatitis C genotype 1-infected patients given peginterferon alpha-2a Curtis L Cooper5 plus ribavirin or peginterferon alpha-2b plus ribavirin were determined using a meta-analysis. Methods: Randomized trials examining peginterferon alpha-2a or peginterferon alpha-2b co- 1Faculty of Health Sciences, University administered with ribavirin for 48 weeks were included. Data were extracted on SVR, relapse, of Ottawa, Ottawa, ON, Canada; For personal use only. 2Department of Clinical Epidemiology and treatment discontinuations for treatment-naïve and treatment-experienced patients. Pooled and Biostatistics, McMaster University, proportions using fixed and random effects meta-analysis were calculated. Hamilton, ON, Canada; 3Centre for Infectious Diseases, Stellenbosch Results: Twenty-six trials provided data on patients treated with peginterferon alpha-2a plus University, Stellenbosch, -
West Nile Virus Restriction in Mosquito and Human Cells: a Virus Under Confinement
Review West Nile Virus Restriction in Mosquito and Human Cells: A Virus under Confinement Marie-France Martin and Sébastien Nisole * Viral Trafficking, Restriction and Innate Signaling Team, Institut de Recherche en Infectiologie de Montpellier (IRIM), CNRS, 34090 Montpellier, France; [email protected] * Correspondence: [email protected] Received: 7 May 2020; Accepted: 27 May 2020; Published: 29 May 2020 Abstract: West Nile virus (WNV) is an emerging neurotropic flavivirus that naturally circulates between mosquitoes and birds. However, WNV has a broad host range and can be transmitted from mosquitoes to several mammalian species, including humans, through infected saliva during a blood meal. Although WNV infections are mostly asymptomatic, 20% to 30% of cases are symptomatic and can occasionally lead to severe symptoms, including fatal meningitis or encephalitis. Over the past decades, WNV-carrying mosquitoes have become increasingly widespread across new regions, including North America and Europe, which constitutes a public health concern. Nevertheless, mosquito and human innate immune defenses can detect WNV infection and induce the expression of antiviral effectors, so-called viral restriction factors, to control viral propagation. Conversely, WNV has developed countermeasures to escape these host defenses, thus establishing a constant arms race between the virus and its hosts. Our review intends to cover most of the current knowledge on viral restriction factors as well as WNV evasion strategies in mosquito and human cells in order to bring an updated overview on WNV–host interactions. Keywords: West Nile virus; restriction factors; interferon; innate immunity; mosquito; viral countermeasures; viral evasion 1. Introduction 1.1. West Nile Virus Incidence West Nile virus (WNV) belongs to the Flaviviridae family, from the Flavivirus genus, which also comprises Zika virus (ZIKV), dengue virus (DENV), tick-borne encephalitis virus (TBEV), and yellow fever virus (YFV).